View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
June 9, 2022

Integral Molecular and Optimeos partner to develop gene therapies

The alliance will merge Integral Molecular’s antibody discovery and mRNA immunisation expertise with Optimeos’ technology.

Integral Molecular has entered a collaboration with Optimeos Life Sciences for developing next-generation messenger ribonucleic acid (mRNA) and deoxyribonucleic acid (DNA)-based gene therapies.

The mRNA and DNA therapeutics will leverage antibody-based molecular targeting to direct vaccines and gene therapies to appropriate tissues in the body of the patient. 

This collaboration will merge the expertise of Integral Molecular in the discovery of antibodies and mRNA immunisation with Optimeos’ technology for drug delivery systems that are based on nanoparticles.

DNA and mRNA therapeutics use the molecular machinery of the patient for encoding proteins. 

The companies intend to encapsulate these therapeutic molecules within nanoparticle spheres that will have antibodies on the outer surface. 

The antibodies can subsequently act on the particles in certain tissues. 

At present, mRNA vaccines and gene therapies are offered through infusion or injection into the body but only a small percentage of the molecules reach their target site. 

By lowering dosages, reducing toxicity and permitting scalable dosing, the proposed molecular targeting strategy could potentially change the vaccine and therapy delivery.

Integral Molecular will use its antibody discovery capabilities against complex cell-surface proteins to offer targeting moieties for the treatments. 

The company’s MPS Antibody Discovery platform is customised to operate with membrane protein targets and utilises mRNA-based immunisation techniques on a regular basis. 

Integral Molecular R&D co-founder and vice-president Joseph Rucker said: “Precision targeting of an isolated cell type with gene therapy holds great promise for genetic diseases and may provide brand-new directions in cancer immunotherapy including in vivo CAR-T cell therapeutics.”

In March 2020, the company announced plans to use its technology platforms to identify Covid-19 vaccines and therapeutics.

Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.

Free Whitepaper

Secure the cell therapy supply chain from bench to bedside

The development of cell therapies is changing healthcare, delivering new hope to thousands of patients around the world. The vein-to-vein workflow for these therapies, however, is not without challenges, many of which will increase as we scale up to treat more patients. Download this free guide from Cytiva to learn more about the challenges and risks associated with the cryogenic supply chain for cell therapies, and how supply chain disruptions can best be mitigated.
by Cytiva Thematic

By clicking the Download Free Whitepaper button, you accept the terms and conditions and acknowledge that your data will be used as described in the Cytiva Thematic privacy policy By downloading this Whitepaper, you acknowledge that we may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Visit our privacy policy for more information about our services, how we may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Pharmaceutical Technology